SinoMab Bioscience Ltd.

As of December 31, 2024, SinoMab Bioscience Ltd. carries a market capitalization of 1.15B, placing it among publicly traded companies globally. Its enterprise value stands at 1.55B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

SinoMab Bioscience Ltd.'s next confirmed earnings release is scheduled for March 22, 2027.

As of December 31, 2024, SinoMab Bioscience Ltd. has 1.09B shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, SinoMab Bioscience Ltd. maintains a current ratio of 0.91, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 22, 2026, SinoMab Bioscience Ltd.'s stock has declined approximately 29.87% over the past 52 weeks. The 50-day moving average sits at 1.11, while the 200-day moving average is 1.38.

As of December 31, 2024, SinoMab Bioscience Ltd. holds 113.74M in cash and equivalents against 513.24M in total debt, resulting in a net debt position of 380.34M. Total book value stands at 205.30M, with working capital of -19.33M providing operational flexibility.